Study: Bypass surgery outperforms Boston Scientific's Taxus

A study of 3,000 patients in 85 U.S. and European hospitals found that 17.8% of those who received Boston Scientific's Taxus drug-coated stent died, experienced a stroke or heart attack, or underwent repeat procedures after a year, compared with 12.1% of those who got bypass surgery. An analysis of the company-sponsored study found no marked difference regarding safety between the two procedures within the first year -- a result that gives patients more options, a cardiologist said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI